Announced today that the companys extremely selective oral kinase inhibitor.

Telatinib is extremely selective, thus eliminating off-target unwanted effects and providing the potential for better efficacy and superior combinability with additional anti-cancer brokers. Telatinib has demonstrated solid antitumor activity in the clinic as a single agent, including objective tumor responses. Telatinib in addition has demonstrated combinability at complete dose with many chemotherapy regimens, including capecitabine/cisplatin in this study, without apparent additive side effects. Related StoriesNew results reveal association between colorectal tumor and melanoma medication treatmentFDA grants accelerated acceptance for Tagrisso to treat individuals with advanced NSCLCNew antenna-like device makes breasts cancer surgery much easier for surgeonsFDA orphan drug designation is intended to encourage companies to develop therapies for the treating diseases that affect fewer than 200,000 people in the usa.Because there have been few long-term research on the basic safety of GMOs, and none that have proven their basic safety, As You Sow is normally urging Abbott’s shareholders to have them removed immediately, or at least keep these things labeled properly. ‘Removing GMOs from dietary products like infant method can only benefit Abbott,’ says Andrew Behar, CEO of As You Sow. ‘As new and credible scientific concerns are raised, consumers are demanding to get a choice in what foods they eat and feed their families. Abbott offers an possibility to lead the industry in being proactive upon this important concern.’ You can read the official news release from As You Sow here: Take action At this point to demand that GMOs end up being removed from SimilacBecause the company is an industry innovator in the baby formula marketplace, Abbott’s potential decision to eliminate GMOs from its products could set a new precedent for the entire industry to follow.